Sarepta shares soar after upgrade implies 322% upside – CNBC


CNBC
Sarepta shares soar after upgrade implies 322% upside
CNBC
The firm raised the price target on the company to $60 per share following further analysis of advisory committee discussions and historical precedence that supports Sarepta’s case for seeking accelerated approval for eteplirsen, its Duchenne’s

and moreĀ >>

Source: shares – Google News

Sharing information is key – Share Dealing Business News UK. Social Commerce and Social Media Management playing a big part. Suaju Ltd